JAMA Surgery:男女性乳腺癌患者接受双侧乳房切除术的利与弊

2015-09-04 MedSci MedSci原创

根据美国癌症协会的调查显示,许多人都没有意识到男性也会患乳腺癌,且他们所占比重为1%。虽然男性乳腺癌患者仅为女性患者的1/100,但2012年美国乳腺外科学会的研究发现,男性乳腺癌患者相比女性而言,生存率更低。女性浸润性乳腺癌患者双侧乳房切除术的比例显著增加,由1998年的2.2%上升至2011年的11%。这一数据引起广大医务人员的关注。去年5月,Medical News Today报道称,发表在

根据美国癌症协会的调查显示,许多人都没有意识到男性也会患乳腺癌,且他们所占比重为1%。虽然男性乳腺癌患者仅为女性患者的1/100,但2012年美国乳腺外科学会的研究发现,男性乳腺癌患者相比女性而言,生存率更低。


女性浸润性乳腺癌患者双侧乳房切除术的比例显著增加,由1998年的2.2%上升至2011年的11%。这一数据引起广大医务人员的关注。

去年5月,Medical News Today报道称,发表在JAMA Surgery的研究称乳腺癌患者接受双侧乳房切除术其实本不必要,因为没有足够证据表明该术式真正有效。最近的一项研究表明,双侧乳房切除术不能降低乳腺癌患者的死亡率。

Ahmedin Jemal和他的同事们开始着手研究接受双侧乳房切除术的男性乳腺癌患者比例是否增高。他们收集了北美中央癌症登记协会(NAACCR)的相关数据,统计了2004-2011年之间共6332名浸润性乳腺癌男性患者的治疗信息和相应数据。

结果显示,在这7年间,接受双乳房切除术的男性患者几乎翻了一番,由2004年的3%上升至2011的5.6%,上升了86.7%。

购有死人医疗保险的年轻白人接受该手术的数目最多,同样条件下的女性患者也较多接受该类型手术。

遗传检测、家族病史、磁共振成像(MRI)、恐惧等因素会影响女性是否接受双侧乳房切除术,但研究人员指出,这些因素是否会影响男性患者接受双侧乳房切除术尚未可知。但是,毫无疑问的是,在接受手术前,医生要与患者合理沟通,根据病情做出全面解释,并尊重患者的决定。
Jemal博士认为,接受双侧乳房切除术患者数目的增加,当不清楚是否可以增加患者的生存率,但是毫无疑问主要目的是为了提高患者的治疗效果和生存质量。

医务人员应该密切关注男性和女性乳腺癌患者的治疗状况,详细告知他们双侧乳房切除术的益处和弊端,以帮助患者做出正确的决定,并能够有利于提高他们的生存质量和治疗效果。

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2021502, encodeId=56e02021502fb, content=<a href='/topic/show?id=31e8e9669d' target=_blank style='color:#2F92EE;'>#GER#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7966, encryptionId=31e8e9669d, topicName=GER)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Tue Jun 07 11:50:00 CST 2016, time=2016-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1877666, encodeId=bbb418e7666b3, content=<a href='/topic/show?id=b013169237f' target=_blank style='color:#2F92EE;'>#surgery#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16923, encryptionId=b013169237f, topicName=surgery)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7db99, createdName=chg121, createdTime=Sat Apr 02 15:50:00 CST 2016, time=2016-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1876711, encodeId=c53d18e671147, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Thu Dec 31 15:50:00 CST 2015, time=2015-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1522378, encodeId=3c7115223e8c1, content=<a href='/topic/show?id=46223e39897' target=_blank style='color:#2F92EE;'>#双侧#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37398, encryptionId=46223e39897, topicName=双侧)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=741b11453403, createdName=wangbingxhy, createdTime=Sun Sep 06 12:50:00 CST 2015, time=2015-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570968, encodeId=71d915e0968b6, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37bc15724202, createdName=hanhaisha2013, createdTime=Sun Sep 06 12:50:00 CST 2015, time=2015-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36422, encodeId=b1cd36422b8, content=看到了, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200609/ef6a57dbe7f1489dad7446b7c5217858/d5e4fe65996c4446a029b0f5d056abb1.jpg, createdBy=6b011518214, createdName=午夜星河, createdTime=Sat Sep 05 06:26:00 CST 2015, time=2015-09-05, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2021502, encodeId=56e02021502fb, content=<a href='/topic/show?id=31e8e9669d' target=_blank style='color:#2F92EE;'>#GER#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7966, encryptionId=31e8e9669d, topicName=GER)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Tue Jun 07 11:50:00 CST 2016, time=2016-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1877666, encodeId=bbb418e7666b3, content=<a href='/topic/show?id=b013169237f' target=_blank style='color:#2F92EE;'>#surgery#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16923, encryptionId=b013169237f, topicName=surgery)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7db99, createdName=chg121, createdTime=Sat Apr 02 15:50:00 CST 2016, time=2016-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1876711, encodeId=c53d18e671147, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Thu Dec 31 15:50:00 CST 2015, time=2015-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1522378, encodeId=3c7115223e8c1, content=<a href='/topic/show?id=46223e39897' target=_blank style='color:#2F92EE;'>#双侧#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37398, encryptionId=46223e39897, topicName=双侧)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=741b11453403, createdName=wangbingxhy, createdTime=Sun Sep 06 12:50:00 CST 2015, time=2015-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570968, encodeId=71d915e0968b6, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37bc15724202, createdName=hanhaisha2013, createdTime=Sun Sep 06 12:50:00 CST 2015, time=2015-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36422, encodeId=b1cd36422b8, content=看到了, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200609/ef6a57dbe7f1489dad7446b7c5217858/d5e4fe65996c4446a029b0f5d056abb1.jpg, createdBy=6b011518214, createdName=午夜星河, createdTime=Sat Sep 05 06:26:00 CST 2015, time=2015-09-05, status=1, ipAttribution=)]
    2016-04-02 chg121
  3. [GetPortalCommentsPageByObjectIdResponse(id=2021502, encodeId=56e02021502fb, content=<a href='/topic/show?id=31e8e9669d' target=_blank style='color:#2F92EE;'>#GER#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7966, encryptionId=31e8e9669d, topicName=GER)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Tue Jun 07 11:50:00 CST 2016, time=2016-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1877666, encodeId=bbb418e7666b3, content=<a href='/topic/show?id=b013169237f' target=_blank style='color:#2F92EE;'>#surgery#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16923, encryptionId=b013169237f, topicName=surgery)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7db99, createdName=chg121, createdTime=Sat Apr 02 15:50:00 CST 2016, time=2016-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1876711, encodeId=c53d18e671147, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Thu Dec 31 15:50:00 CST 2015, time=2015-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1522378, encodeId=3c7115223e8c1, content=<a href='/topic/show?id=46223e39897' target=_blank style='color:#2F92EE;'>#双侧#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37398, encryptionId=46223e39897, topicName=双侧)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=741b11453403, createdName=wangbingxhy, createdTime=Sun Sep 06 12:50:00 CST 2015, time=2015-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570968, encodeId=71d915e0968b6, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37bc15724202, createdName=hanhaisha2013, createdTime=Sun Sep 06 12:50:00 CST 2015, time=2015-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36422, encodeId=b1cd36422b8, content=看到了, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200609/ef6a57dbe7f1489dad7446b7c5217858/d5e4fe65996c4446a029b0f5d056abb1.jpg, createdBy=6b011518214, createdName=午夜星河, createdTime=Sat Sep 05 06:26:00 CST 2015, time=2015-09-05, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2021502, encodeId=56e02021502fb, content=<a href='/topic/show?id=31e8e9669d' target=_blank style='color:#2F92EE;'>#GER#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7966, encryptionId=31e8e9669d, topicName=GER)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Tue Jun 07 11:50:00 CST 2016, time=2016-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1877666, encodeId=bbb418e7666b3, content=<a href='/topic/show?id=b013169237f' target=_blank style='color:#2F92EE;'>#surgery#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16923, encryptionId=b013169237f, topicName=surgery)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7db99, createdName=chg121, createdTime=Sat Apr 02 15:50:00 CST 2016, time=2016-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1876711, encodeId=c53d18e671147, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Thu Dec 31 15:50:00 CST 2015, time=2015-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1522378, encodeId=3c7115223e8c1, content=<a href='/topic/show?id=46223e39897' target=_blank style='color:#2F92EE;'>#双侧#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37398, encryptionId=46223e39897, topicName=双侧)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=741b11453403, createdName=wangbingxhy, createdTime=Sun Sep 06 12:50:00 CST 2015, time=2015-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570968, encodeId=71d915e0968b6, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37bc15724202, createdName=hanhaisha2013, createdTime=Sun Sep 06 12:50:00 CST 2015, time=2015-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36422, encodeId=b1cd36422b8, content=看到了, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200609/ef6a57dbe7f1489dad7446b7c5217858/d5e4fe65996c4446a029b0f5d056abb1.jpg, createdBy=6b011518214, createdName=午夜星河, createdTime=Sat Sep 05 06:26:00 CST 2015, time=2015-09-05, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2021502, encodeId=56e02021502fb, content=<a href='/topic/show?id=31e8e9669d' target=_blank style='color:#2F92EE;'>#GER#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7966, encryptionId=31e8e9669d, topicName=GER)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Tue Jun 07 11:50:00 CST 2016, time=2016-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1877666, encodeId=bbb418e7666b3, content=<a href='/topic/show?id=b013169237f' target=_blank style='color:#2F92EE;'>#surgery#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16923, encryptionId=b013169237f, topicName=surgery)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7db99, createdName=chg121, createdTime=Sat Apr 02 15:50:00 CST 2016, time=2016-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1876711, encodeId=c53d18e671147, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Thu Dec 31 15:50:00 CST 2015, time=2015-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1522378, encodeId=3c7115223e8c1, content=<a href='/topic/show?id=46223e39897' target=_blank style='color:#2F92EE;'>#双侧#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37398, encryptionId=46223e39897, topicName=双侧)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=741b11453403, createdName=wangbingxhy, createdTime=Sun Sep 06 12:50:00 CST 2015, time=2015-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570968, encodeId=71d915e0968b6, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37bc15724202, createdName=hanhaisha2013, createdTime=Sun Sep 06 12:50:00 CST 2015, time=2015-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36422, encodeId=b1cd36422b8, content=看到了, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200609/ef6a57dbe7f1489dad7446b7c5217858/d5e4fe65996c4446a029b0f5d056abb1.jpg, createdBy=6b011518214, createdName=午夜星河, createdTime=Sat Sep 05 06:26:00 CST 2015, time=2015-09-05, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2021502, encodeId=56e02021502fb, content=<a href='/topic/show?id=31e8e9669d' target=_blank style='color:#2F92EE;'>#GER#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7966, encryptionId=31e8e9669d, topicName=GER)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Tue Jun 07 11:50:00 CST 2016, time=2016-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1877666, encodeId=bbb418e7666b3, content=<a href='/topic/show?id=b013169237f' target=_blank style='color:#2F92EE;'>#surgery#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16923, encryptionId=b013169237f, topicName=surgery)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7db99, createdName=chg121, createdTime=Sat Apr 02 15:50:00 CST 2016, time=2016-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1876711, encodeId=c53d18e671147, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Thu Dec 31 15:50:00 CST 2015, time=2015-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1522378, encodeId=3c7115223e8c1, content=<a href='/topic/show?id=46223e39897' target=_blank style='color:#2F92EE;'>#双侧#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37398, encryptionId=46223e39897, topicName=双侧)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=741b11453403, createdName=wangbingxhy, createdTime=Sun Sep 06 12:50:00 CST 2015, time=2015-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570968, encodeId=71d915e0968b6, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37bc15724202, createdName=hanhaisha2013, createdTime=Sun Sep 06 12:50:00 CST 2015, time=2015-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36422, encodeId=b1cd36422b8, content=看到了, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200609/ef6a57dbe7f1489dad7446b7c5217858/d5e4fe65996c4446a029b0f5d056abb1.jpg, createdBy=6b011518214, createdName=午夜星河, createdTime=Sat Sep 05 06:26:00 CST 2015, time=2015-09-05, status=1, ipAttribution=)]
    2015-09-05 午夜星河

    看到了

    0

相关资讯

STM:新型“突变-追踪”血液检查预测乳癌复发

科学家开发出了一种检测乳腺癌的血液测试,该测试能够识别哪些病人会在治疗后复发。癌症研究所的研究人员能够在癌症积累发展和传播时追踪关键突变,而不需要活检。他们希望通过在血液样本中破译DNA编码来鉴别病人中可能致命的特异突变,并相应地调整治疗。该研究发表在《科学转化医学》杂志上,“液体活检”是重要的一步,可彻底改变乳腺癌治疗。研究人员从55例接受手术后化疗的早期乳腺癌患者中提出肿瘤和血液样本。通过对患

JCO:乳腺癌风险评估新模型

 2015年,仅在美国就有超过231000名女性被诊断为乳腺癌,大约4万人最终将死于乳腺癌。美国预防服务工作者和美国临床肿瘤学会推荐女性进行常规的风险评估以作出合适的治疗决策来降低患乳腺癌的风险。美国每年有大约160万人接受乳腺组织切片检查。有增殖性乳腺损伤的女性或许是一级预防的主要对象。乳房密度和良性乳房疾病(benign breast disease,BBD)是重要的乳腺癌风险因素。

J CLIN ONCOL:联合乳腺密度与乳腺良性病变以准确识别乳腺癌高危女性

J CLIN ONCOL:联合乳腺密度与乳腺良性病变以准确识别乳腺癌高危女性患有乳腺增生性疾病的女性本是乳腺癌的初级预防对象,但是却很少有将良性病变纳入评估乳腺癌发病风险的危险模型。本研究将乳腺良性病变(BBD)纳入美国乳腺癌监测联盟(BCSC)风险模型中,该模型是唯一采用乳腺密度来预测乳腺癌发生的模型。该研究使用2000-2010乳腺癌发病率的SEER数据以及2010校正死亡的竞争风险人口统计学

JAMA Oncol:乳腺导管原位癌真的有必要手术吗?

乳腺癌是全世界妇女的头号杀手,大约占所有妇女癌症的16%。乳腺癌可根据肿块大小和扩散情况而分为很多期。导管原位癌(DCIS),即0期乳腺癌,大约占了乳腺癌患者的20%。它的特征是肿块局限在一处,还未扩散到淋巴结。 在这种疾病发现之后,绝大多数妇女会接受手术治疗:要么是乳房肿瘤切除术,切除乳房中的肿块;要么是乳房切除术或双乳切除术,切除一侧或两侧乳房。然而,JAMA Oncology上最新发表的一

Nat Commun:定位乳腺癌复发早期和微转移

凯斯西储大学研究人员已经证明,磁共振成像(MRI)可检测乳腺癌的复发和快速生长的肿瘤的早期迹象。研究人员使用的这种技术可以检测到只有几百个细胞大小的微肿瘤,具有从低风险肿瘤中区分侵袭性肿瘤的可能性,推动了成像技术的界限。提供改进的早期复发乳腺癌患者的检测方法。这项研究在线发表在近日的Nature Communications。三分之一乳腺癌患者最终都发展远处器官的转移,伴随死亡风险的增加。 因为早

CA权威回顾--癌症可以药物预防吗?

可以预防的癌症 乳腺癌 宫颈癌 食道癌 预防